JP2017518326A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518326A5
JP2017518326A5 JP2016573030A JP2016573030A JP2017518326A5 JP 2017518326 A5 JP2017518326 A5 JP 2017518326A5 JP 2016573030 A JP2016573030 A JP 2016573030A JP 2016573030 A JP2016573030 A JP 2016573030A JP 2017518326 A5 JP2017518326 A5 JP 2017518326A5
Authority
JP
Japan
Prior art keywords
amino
pyrazolo
ethyl
indolizin
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573030A
Other languages
English (en)
Japanese (ja)
Other versions
JP6730200B2 (ja
JP2017518326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/063390 external-priority patent/WO2015193263A1/en
Publication of JP2017518326A publication Critical patent/JP2017518326A/ja
Publication of JP2017518326A5 publication Critical patent/JP2017518326A5/ja
Application granted granted Critical
Publication of JP6730200B2 publication Critical patent/JP6730200B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573030A 2014-06-17 2015-06-16 ホスホイノシチド3−キナーゼ阻害剤としてのインドリジン誘導体 Expired - Fee Related JP6730200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172764.4 2014-06-17
EP14172764 2014-06-17
PCT/EP2015/063390 WO2015193263A1 (en) 2014-06-17 2015-06-16 Indolizine derivatives as phoshoinositide 3-kinases inhibitors

Publications (3)

Publication Number Publication Date
JP2017518326A JP2017518326A (ja) 2017-07-06
JP2017518326A5 true JP2017518326A5 (https=) 2018-07-19
JP6730200B2 JP6730200B2 (ja) 2020-07-29

Family

ID=50942205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573030A Expired - Fee Related JP6730200B2 (ja) 2014-06-17 2015-06-16 ホスホイノシチド3−キナーゼ阻害剤としてのインドリジン誘導体

Country Status (23)

Country Link
US (1) US9527869B2 (https=)
EP (1) EP3157920B1 (https=)
JP (1) JP6730200B2 (https=)
KR (1) KR102420322B1 (https=)
CN (1) CN106661019B (https=)
AR (1) AR100879A1 (https=)
AU (1) AU2015276264B2 (https=)
BR (1) BR112016028845B1 (https=)
CA (1) CA2952287C (https=)
CL (1) CL2016003214A1 (https=)
EA (1) EA031409B1 (https=)
ES (1) ES2750791T3 (https=)
GE (2) GEAP201814349A (https=)
IL (1) IL249554A0 (https=)
MX (1) MX373129B (https=)
PE (1) PE20170303A1 (https=)
PH (1) PH12016502291A1 (https=)
PL (1) PL3157920T3 (https=)
SG (1) SG11201610473QA (https=)
TN (1) TN2016000555A1 (https=)
TW (1) TW201625611A (https=)
WO (1) WO2015193263A1 (https=)
ZA (1) ZA201608637B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
KR101815193B1 (ko) * 2015-12-29 2018-01-30 (주)스파크바이오파마 PPARγ 인산화 저해제 및 이를 포함하는 약학적 조성물
WO2017123991A1 (en) * 2016-01-15 2017-07-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
EP3411375B1 (en) * 2016-02-04 2020-08-05 Chiesi Farmaceutici S.p.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
CN109963854B (zh) 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
CN108129480A (zh) * 2018-03-11 2018-06-08 赵艳阳 一种含芳杂环亚甲基吲嗪衍生物的制备方法
EP4685140A1 (en) * 2018-06-04 2026-01-28 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
AU2020252904A1 (en) * 2019-04-04 2021-11-18 Chiesi Farmaceutici S.P.A. Isochromene derivatives as phosphoinositide 3-kinases inhibitors
CN110156785B (zh) * 2019-04-15 2020-08-28 浙江大学 吲唑类化合物及其制备方法和应用
US20230102520A1 (en) * 2019-07-03 2023-03-30 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
KR102866487B1 (ko) 2023-01-06 2025-10-01 연세대학교 산학협력단 새로운 인돌리진-피롤로피리미딘 하이브리드 유도체 제조방법 및 이를 포함하는 항암제 조성물
WO2024186827A2 (en) * 2023-03-06 2024-09-12 The Regents Of The University Of California Novel host-directed therapeutic agent for the treatment of infectious diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2010027762A1 (en) * 2008-09-04 2010-03-11 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
KR20140069235A (ko) * 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온

Similar Documents

Publication Publication Date Title
JP2017518326A5 (https=)
AU2010249380B2 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP2021528467A5 (https=)
TW202423440A (zh) Kras g12c突變蛋白的系鏈之雜環抑制劑及其用途
AU2015276264B2 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
HRP20240935T1 (hr) Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
AU2019216728A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
JPWO2020005873A5 (https=)
JP2019535664A5 (https=)
WO2022093856A1 (en) Heterocyclic spiro compounds and methods of use
CA2687035A1 (en) Amino-heterocyclic compounds
JP2013523884A5 (https=)
JP2015533822A5 (https=)
AU2011343477A1 (en) Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
HRP20192151T1 (hr) Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza
JP2013518823A5 (https=)
RU2020127848A (ru) Производные 4-гидроксипиперидина и их применение в качестве ингибиторов убиквитин-специфической протеазы 19 (usp19)
TW202412783A (zh) 酪胺酸激酶2抑制劑及其用途
WO2025230878A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof
NZ771414A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
AU2015201991A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases